spiperone has been researched along with Anochlesia in 55 studies
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.
spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metoclopramide is a strong postsynaptic dopamine D(2) receptor blocker with no antipsychotic potency." | 1.35 | Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats. ( Agovic, MS; Banerjee, SP; Lidsky, TI; Yablonsky-Alter, E, 2008) |
| " The findings indicated that, on day 1 to day 6, a greater development of tolerance was seen in the group of mice treated at 9:00 AM, and catalepsy behavior exhibited a significant difference between the two dosing times (P < 0." | 1.31 | Dosing time-dependent tolerance of catalepsy by repetitive administration of haloperidol in mice. ( Higuchi, S; Ohdo, S; Viyoch, J; Yukawa, E, 2001) |
| "7e exhibits a high reversal of catalepsy induced by haloperidol indicating its atypical antipsychotic nature." | 1.30 | Synthesis and preliminary pharmacological investigations of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine derivatives as potential atypical antipsychotic agents in mice. ( Brust, P; Gupta, CN; Parimoo, P; Raghavan, SA; Rangisetty, JB; Sridhar, N; Srinivas, P; Subramanian, AR; Veeranjaneyulu, A, 1999) |
| "Tolerance to SCH 23390-induced catalepsy did not develop during the 11-day treatment, and Tyr-MIF-1 had no effect on SCH 23390-induced catalepsy." | 1.29 | Tyr-MIF-1 attenuates development of tolerance to spiperone-induced catalepsy in rats. ( Kastin, AJ; Kostrzewa, RM, 1993) |
| "The incidence of haloperidol-induced catalepsy was investigated in mice whose postsynaptic dopamine (DA) receptors in the striatum had been upregulated by denervation with 6-hydroxydopamine (6-OHDA)." | 1.28 | Upregulation of postsynaptic dopamine receptors in the striatum does not influence haloperidol-induced catalepsy in mice. ( Iwata, S; Izumi, K; Nomoto, M, 1992) |
| "Catalepsy-sensitive Fisher rats and catalepsy-resistant Brown Norway rats were treated for 14 days with haloperidol at a dose of either 1 mg/kg or 5 mg/kg daily." | 1.28 | Difference in catalepsy response in inbred rats during chronic haloperidol treatment is not predictive of the intensity of behavioral hypersensitivity which subsequently develops. ( Kane, JM; Kinon, BJ, 1989) |
| "The dose of 3 necessary to produce catalepsy in rats is much greater than that required for activity in behavioral tests predictive of antipsychotic efficacy, for example the suppression of high base line medial forebrain bundle self-stimulation in rats." | 1.27 | Examination of a series of 8-[3-[bis(4-fluorophenyl)amino]propyl]-1-aryl-1,3,8- triazaspiro[4.5]decan-4-ones as potential antipsychotic agents. ( Butler, DE; Coughenour, LL; DeWald, HA; Downs, DA; Lewis, EP; Lobbestael, SJ; Pattison, IC; Poschel, BP; Tecle, H; Wise, LD, 1985) |
| "Rats given EEDQ 3-10 mg/kg i." | 1.27 | Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. ( Creese, I; Hamblin, MW, 1983) |
| "Remoxipride was shown to be a selective dopamine D2 receptor antagonist since it displaced [3H]spiperone (IC50 = 1570 nM) but not [3H]flupentixol (IC50 greater than 100 000 nM) in rat striatum, and did not inhibit striatal DA-sensitive adenylate cyclase in vitro (IC50 greater than 100 000 nM)." | 1.27 | Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. ( Angeby, K; Florvall, L; Hall, H; Köhler, C; Lindbom, LO; Magnusson, O; Ogren, SO, 1984) |
| " An experimental study of the long-term administrations of haloperidol revealed the formation of adaptation to the drug which can be overcome by a zigzag-like sharp elevation of the dosage followed by rapid reduction to the baseline level." | 1.27 | [Various methods of overcoming secondary resistance to treatment developing in relation to adaptation to psychotropic drugs during long-term treatment (clinico-experimental study)]. ( Allikmets, LKh; Avrutskiĭ, GIa; Beliakov, AV; Neduva, AA; Zharkovskiĭ, AM, 1984) |
| " Catalepsy induced by acute administration of haloperidol, trifluoperazine or cis-flupenthixol was reduced by continuous chronic intake of cis-flupenthixol." | 1.27 | Alterations in different populations of striatal dopamine receptors produced by 18 months continuous administration of cis- or trans-flupenthixol to rats. ( Fleminger, S; Hall, MD; Jenner, P; Marsden, CD; Murugaiah, K; Theodorou, A, 1984) |
| "(+)-Thioridazine was shown to have 2." | 1.27 | Receptor affinity, neurochemistry and behavioral characteristics of the enantiomers of thioridazine: evidence for different stereoselectivities at D1 and D2 receptors in rat brain. ( Babb, S; Baldessarini, RJ; Bird, ED; Campbell, A; Cohen, BM; Froimowitz, M; Hrbek, C; Kula, N; Svendsen, CN; Teicher, MH, 1988) |
| "In rats, MCP produced catalepsy and inhibited apomorphine-induced stereotypy, locomotor activity, and rotational behavior." | 1.27 | Pharmacologic evaluation of dopaminergic receptor blockade by metoclopramide. ( Fahn, S; Hassan, MN; Higgins, D; Kuhn, C; Reches, A, 1986) |
| "Prior to the induction of catalepsy and after recovery from it, mice display the entire range of typical apomorphine-induced behavior including sniffing, climbing, gnawing, and licking." | 1.27 | Simultaneous catalepsy and apomorphine-induced stereotypic behavior in mice. ( Randall, PK; Yurek, DM, 1985) |
| "It is proposed that the decrement in catalepsy occurring between 10 and 15 days of age is related to increased dopaminergic activity in the neostriatum." | 1.26 | Dopaminergic antagonism and catalepsy in the developing rat. ( Baez, LA; Burt, DK; Granneman, J; Shanklin, C, 1979) |
| "Spiperone produced catalepsy in rats 1, 5 and 10 days old, and also in adults." | 1.26 | Postnatal development of dopaminergic and cholinergic catalepsy in the rat. ( Baez, LA; Eskridge, NK; Schein, R, 1976) |
| "The pilocarpine-catalepsy was abolished by atropine, promethazine and nomifensine and unaffected by tricyclic antidepressants." | 1.26 | On the anticataleptic action of cyproheptadine. ( Klimek, V; Maj, J; Rawlów, A; Sarnek, J, 1976) |
| "PCA had no influence on catalepsy induced by neuroleptics from the group of butyrophenones, potentiated the cataleptic action of reserpine in the dose of 5 mg/kg, and suppressed catalepsy induced by reserpine in the dose of 10 mg/kg." | 1.25 | The effect of 5-hydroxytrytamine synthesis inhibitors on neuroleptic-induced catalepsy in rats. ( Baran, L; Sarnek, J, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (69.09) | 18.7374 |
| 1990's | 12 (21.82) | 18.2507 |
| 2000's | 5 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wise, LD | 1 |
| Pattison, IC | 1 |
| Butler, DE | 1 |
| DeWald, HA | 1 |
| Lewis, EP | 1 |
| Lobbestael, SJ | 1 |
| Tecle, H | 1 |
| Coughenour, LL | 1 |
| Downs, DA | 1 |
| Poschel, BP | 1 |
| Millan, MJ | 1 |
| Peglion, JL | 1 |
| Vian, J | 1 |
| Rivet, JM | 1 |
| Brocco, M | 1 |
| Gobert, A | 1 |
| Newman-Tancredi, A | 1 |
| Dacquet, C | 1 |
| Bervoets, K | 1 |
| Girardon, S | 1 |
| Bjartmar, C | 1 |
| Trapp, BD | 1 |
| Park, WK | 1 |
| Jeong, D | 1 |
| Cho, H | 1 |
| Lee, SJ | 1 |
| Cha, MY | 1 |
| Pae, AN | 1 |
| Choi, KI | 1 |
| Koh, HY | 1 |
| Kong, JY | 1 |
| Agovic, MS | 1 |
| Yablonsky-Alter, E | 1 |
| Lidsky, TI | 1 |
| Banerjee, SP | 1 |
| Chiu, S | 1 |
| Paulose, CS | 1 |
| Mishra, RK | 1 |
| Dawbarn, D | 1 |
| Pycock, C | 1 |
| Hamblin, MW | 1 |
| Creese, I | 1 |
| Costall, B | 1 |
| Dannenburg, WN | 1 |
| Johnson, DN | 1 |
| Naylor, RJ | 1 |
| Köhler, C | 3 |
| Ogren, SO | 3 |
| Fuxe, K | 2 |
| Hall, H | 1 |
| Magnusson, O | 1 |
| Lindbom, LO | 1 |
| Angeby, K | 1 |
| Florvall, L | 1 |
| Bacopoulos, NG | 1 |
| Mjörndal, T | 1 |
| Persson, SA | 1 |
| Crocker, AD | 1 |
| Overstreet, DH | 2 |
| Avrutskiĭ, GIa | 1 |
| Allikmets, LKh | 1 |
| Neduva, AA | 1 |
| Zharkovskiĭ, AM | 2 |
| Beliakov, AV | 1 |
| Murugaiah, K | 1 |
| Fleminger, S | 1 |
| Hall, MD | 1 |
| Theodorou, A | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Matvienko, OA | 1 |
| Nurk, AM | 1 |
| Crider, AM | 1 |
| Hemdi, TF | 1 |
| Hassan, MN | 2 |
| Fahn, S | 2 |
| Lowery, SP | 1 |
| Barkley, P | 1 |
| Baez, LA | 3 |
| Atterwill, CK | 1 |
| Kajiyama, H | 1 |
| Nomura, Y | 1 |
| Golembiowska-Nikitin, K | 1 |
| Pilc, A | 1 |
| Vetulani, J | 1 |
| Dorris, RL | 2 |
| Kikuchi, T | 2 |
| Tottori, K | 1 |
| Uwahodo, Y | 1 |
| Hirose, T | 1 |
| Miwa, T | 1 |
| Oshiro, Y | 1 |
| Morita, S | 1 |
| Kolasa, K | 1 |
| Consolo, S | 1 |
| Costi, P | 1 |
| Kleinrok, Z | 1 |
| Zecca, L | 1 |
| Krisch, I | 1 |
| Bole-Vunduk, B | 1 |
| Pepelnak, M | 1 |
| Lavric, B | 1 |
| Ocvirk, A | 1 |
| Budihna, MV | 1 |
| Sket, D | 1 |
| Kostrzewa, RM | 1 |
| Kastin, AJ | 1 |
| Maj, J | 2 |
| Rogóz, Z | 1 |
| Skuza, G | 1 |
| Kołodziejczyk, K | 1 |
| Srinivas, P | 1 |
| Subramanian, AR | 1 |
| Brust, P | 1 |
| Raghavan, SA | 1 |
| Rangisetty, JB | 1 |
| Gupta, CN | 1 |
| Sridhar, N | 1 |
| Veeranjaneyulu, A | 1 |
| Parimoo, P | 1 |
| Geurts, M | 1 |
| Hermans, E | 1 |
| Maloteaux, JM | 1 |
| Usiello, A | 1 |
| Baik, JH | 1 |
| Rougé-Pont, F | 1 |
| Picetti, R | 1 |
| Dierich, A | 1 |
| LeMeur, M | 1 |
| Piazza, PV | 1 |
| Borrelli, E | 1 |
| Viyoch, J | 1 |
| Ohdo, S | 1 |
| Yukawa, E | 1 |
| Higuchi, S | 1 |
| Pedigo, NW | 1 |
| Schallert, T | 1 |
| Ling, NC | 1 |
| Ragan, P | 1 |
| Reisine, TD | 1 |
| Yamamura, HI | 1 |
| Höllt, V | 1 |
| Czlonkowski, A | 1 |
| Herz, A | 1 |
| Francis, N | 1 |
| Marley, E | 1 |
| Stephenson, JD | 1 |
| Burt, DK | 1 |
| Granneman, J | 1 |
| Shanklin, C | 1 |
| Haglund, L | 1 |
| Angeby, T | 1 |
| Chiodo, LA | 1 |
| Caggiula, AR | 1 |
| Saller, CF | 1 |
| Eskridge, NK | 1 |
| Schein, R | 1 |
| Sarnek, J | 2 |
| Klimek, V | 1 |
| Rawlów, A | 1 |
| Baran, L | 1 |
| Iwata, S | 1 |
| Izumi, K | 1 |
| Nomoto, M | 1 |
| Sagratella, S | 1 |
| Scotti de Carolis, A | 1 |
| Pèzzola, A | 1 |
| Popoli, P | 1 |
| Hirose, A | 1 |
| Kato, T | 1 |
| Ohno, Y | 1 |
| Shimizu, H | 1 |
| Tanaka, H | 1 |
| Nakamura, M | 1 |
| Katsube, J | 1 |
| Kinon, BJ | 1 |
| Kane, JM | 1 |
| New, JS | 1 |
| Christopher, WL | 1 |
| Yevich, JP | 1 |
| Butler, R | 1 |
| Schlemmer, RF | 1 |
| VanderMaelen, CP | 1 |
| Cipollina, JA | 1 |
| Svendsen, CN | 1 |
| Froimowitz, M | 1 |
| Hrbek, C | 1 |
| Campbell, A | 1 |
| Kula, N | 1 |
| Baldessarini, RJ | 1 |
| Cohen, BM | 1 |
| Babb, S | 1 |
| Teicher, MH | 1 |
| Bird, ED | 1 |
| Henning, R | 1 |
| Lattrell, R | 1 |
| Gerhards, HJ | 1 |
| Leven, M | 1 |
| Farabegoli, C | 1 |
| Merlo Pich, E | 1 |
| Cimino, M | 1 |
| Agnati, LF | 1 |
| Campbell, W | 1 |
| Clark, MS | 1 |
| Mitchell, PJ | 1 |
| Needham, PL | 1 |
| Semple, JM | 1 |
| Reches, A | 1 |
| Kuhn, C | 1 |
| Higgins, D | 1 |
| Watanabe, H | 1 |
| Uramoto, H | 1 |
| Maeda-Hagiwara, M | 1 |
| Yurek, DM | 1 |
| Randall, PK | 1 |
| Hruska, RE | 1 |
55 other studies available for spiperone and Anochlesia
| Article | Year |
|---|---|
Examination of a series of 8-[3-[bis(4-fluorophenyl)amino]propyl]-1-aryl-1,3,8- triazaspiro[4.5]decan-4-ones as potential antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Cebus; Chemical Phen | 1985 |
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin
Topics: 2-Naphthylamine; Animals; Body Temperature Regulation; Catalepsy; CHO Cells; Cricetinae; Dopamine An | 1995 |
Axonal degeneration and progressive neurologic disability in multiple sclerosis.
Topics: Animals; Apomorphine; Behavior, Animal; Benzazepines; Binding, Competitive; Catalepsy; Dopamine Agon | 2003 |
KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Topics: Animals; Antipsychotic Agents; Body Temperature; Catalepsy; Cell Line; Dopamine Uptake Inhibitors; G | 2005 |
Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats.
Topics: Animals; Behavior, Animal; Binding, Competitive; Catalepsy; Cerebral Cortex; Dizocilpine Maleate; Do | 2008 |
Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings.
Topics: Animals; Apomorphine; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Humans; Kinetics; Ma | 1981 |
Differential sensitivity to neuroleptic drugs of cerebral dopamine receptors following chronic treatment of rats with trifluoperazine.
Topics: Animals; Antipsychotic Agents; Brain; Catalepsy; Female; Haloperidol; Humans; Radioligand Assay; Rat | 1981 |
Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
Topics: Adrenergic alpha-Antagonists; Animals; Apomorphine; Catalepsy; Dose-Response Relationship, Drug; Hum | 1983 |
Aminoalkylindoles: atypical dopamine antagonists.
Topics: Amphetamine; Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dopamine Antagonists; Halope | 1983 |
Studies on the mechanism of action of substituted benzamide drugs.
Topics: Animals; Antipsychotic Agents; Apomorphine; Benzamides; Brain; Catalepsy; Corpus Striatum; Humans; H | 1984 |
Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Benzamides; Binding | 1984 |
Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
Topics: Animals; Antipsychotic Agents; Brain; Butaclamol; Catalepsy; Dopamine; Fluphenazine; Haloperidol; Hu | 1981 |
The relation between spiperone binding, behavioural changes, and in vivo tyrosine hydroxylation in the rat striatum.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Binding Sites; Catalepsy; Corpus Striatum; Di | 1983 |
Modification of the behavioural effects of haloperidol and of dopamine receptor regulation by altered thyroid status.
Topics: Animals; Behavior, Animal; Body Temperature; Catalepsy; Haloperidol; Humans; Hyperthyroidism; Hypoth | 1984 |
[Various methods of overcoming secondary resistance to treatment developing in relation to adaptation to psychotropic drugs during long-term treatment (clinico-experimental study)].
Topics: Adult; Animals; Catalepsy; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Drug | 1984 |
Alterations in different populations of striatal dopamine receptors produced by 18 months continuous administration of cis- or trans-flupenthixol to rats.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Body Weight; Catalepsy; Corpus Striatum; Flupenthixol; Huma | 1984 |
[Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
Topics: Animals; Apomorphine; Catalepsy; Corpus Striatum; Dose-Response Relationship, Drug; Drug Synergism; | 1984 |
Synthesis and dopaminergic activity of 3-(3,4-dihydroxyphenyl)-1-n-propylpyrrolidine hydrobromide.
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Chemical Phenomena; Chemistry; Dopamine; Humans; | 1984 |
The influence of anterior neostriatal lesions on the behavioural effects of spiroperidol in rats.
Topics: Animals; Behavior, Animal; Butyrophenones; Catalepsy; Caudate Nucleus; Humans; Male; Putamen; Rats; | 1980 |
Effect of acute and chronic tri-iodothyronine (T3) administration to rats on central 5-HT and dopamine-mediated behavioural responses and related brain biochemistry.
Topics: Animals; Behavior, Animal; Brain Chemistry; Catalepsy; Dopamine; Humans; Male; Motor Activity; Rats; | 1981 |
Alteration in dopaminergic and muscarinic cholinergic receptors after subchronic treatment with haloperidol in the developing rat brain.
Topics: Animals; Animals, Newborn; Brain; Catalepsy; Corpus Striatum; Female; Haloperidol; Humans; Male; Mot | 1981 |
Cataleptogenic doses of morphine suppress 3H-spiroperidol binding to striatal membranes.
Topics: Animals; Butyrophenones; Catalepsy; Corpus Striatum; Humans; Male; Morphine; Rats; Rats, Inbred Stra | 1982 |
Evidence for an action of araboascorbic acid on dopaminergic pathways of the corpus striatum.
Topics: Animals; Ascorbic Acid; Catalepsy; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Antagonists; | 1995 |
7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Catalepsy; Corpus Striatu | 1995 |
Behavioral and biochemical changes after bilateral electrolytic lesions of the red nucleus of rat.
Topics: Animals; Apomorphine; Azepines; Behavior, Animal; Body Temperature; Brain Chemistry; Catalepsy; Dopa | 1995 |
Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Antipsychotic Agents; Benzazepines; Blood Pressure | 1994 |
Tyr-MIF-1 attenuates development of tolerance to spiperone-induced catalepsy in rats.
Topics: Amino Acid Sequence; Animals; Benzazepines; Catalepsy; Drug Administration Schedule; Drug Tolerance; | 1993 |
The behavioural effects of pramipexole, a novel dopamine receptor agonist.
Topics: Animals; Antiparkinson Agents; Benzazepines; Benzothiazoles; Body Temperature; Catalepsy; Clozapine; | 1997 |
Synthesis and preliminary pharmacological investigations of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine derivatives as potential atypical antipsychotic agents in mice.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Binding, Competitive; Brain Chemistry; | 1999 |
Enhanced striatal dopamine D(2) receptor-induced [35S]GTPgammaS binding after haloperidol treatment.
Topics: Animals; Apomorphine; Binding, Competitive; Catalepsy; Corpus Striatum; Dopamine; Dopamine Agonists; | 1999 |
Distinct functions of the two isoforms of dopamine D2 receptors.
Topics: Animals; Apomorphine; Benzazepines; Catalepsy; Chimera; Dopamine; Dopamine Agonists; Dopamine Antago | 2000 |
Dosing time-dependent tolerance of catalepsy by repetitive administration of haloperidol in mice.
Topics: Animals; Antipsychotic Agents; Catalepsy; Circadian Rhythm; Dopamine Antagonists; Dose-Response Rela | 2001 |
Inhibition of in vivo 3H-spiperone binding by the proposed antipsychotic Des-Tyr1-gamma-endorphin.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Blepharoptosis; Brain; Butyrophenones; Catalepsy; E | 1979 |
The demonstration in vivo of specific binding sites for neuroleptic drugs in mouse brain.
Topics: Animals; Apomorphine; Brain; Catalepsy; Chlorpromazine; Dibenzocycloheptenes; Dopamine; Haloperidol; | 1977 |
Effects of spiperone on self-stimulation and other activities of the Mongolian gerbil.
Topics: Animals; Butyrophenones; Catalepsy; Conditioning, Operant; Dose-Response Relationship, Drug; Female; | 1978 |
Dopaminergic antagonism and catalepsy in the developing rat.
Topics: Aging; Animals; Catalepsy; Dopamine; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Rats; | 1979 |
Regional displacement by sulpiride of [3H]spiperone binding in vivo. Biochemical and behavioural evidence for a preferential action of limbic and nigral dopamine receptors.
Topics: Animals; Apomorphine; Binding, Competitive; Brain; Butyrophenones; Catalepsy; Haloperidol; Humans; M | 1979 |
Estrogen increases both spiperone-induced catalepsy and brain levels of [3H]spiperone in the rat.
Topics: Animals; Blood-Brain Barrier; Brain; Butyrophenones; Castration; Catalepsy; Dose-Response Relationsh | 1979 |
Postnatal development of dopaminergic and cholinergic catalepsy in the rat.
Topics: Aging; Animals; Butyrophenones; Catalepsy; Catecholamines; Female; Humans; Male; Neurons; Pilocarpin | 1976 |
On the anticataleptic action of cyproheptadine.
Topics: Animals; Atropine; Catalepsy; Clomipramine; Cyproheptadine; Desipramine; Female; Fluphenazine; Human | 1976 |
The effect of 5-hydroxytrytamine synthesis inhibitors on neuroleptic-induced catalepsy in rats.
Topics: Amphetamines; Catalepsy; Fluphenazine; Humans; p-Chloroamphetamine; Pimozide; Reserpine; Serotonin; | 1975 |
Upregulation of postsynaptic dopamine receptors in the striatum does not influence haloperidol-induced catalepsy in mice.
Topics: Animals; Biogenic Monoamines; Catalepsy; Corpus Striatum; Haloperidol; Kinetics; Male; Mice; Mice, I | 1992 |
Behavioural and electoencephalographic interactions between haloperidol and PCP/sigma ligands in the rat.
Topics: 2-Amino-5-phosphonovalerate; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; | 1991 |
Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Brain Chemistry; Catalepsy; Dopamine Antagonists; I | 1990 |
Difference in catalepsy response in inbred rats during chronic haloperidol treatment is not predictive of the intensity of behavioral hypersensitivity which subsequently develops.
Topics: Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Haloperidol; Male; Rats; Rats, Inbred F344; R | 1989 |
Interactions of nicotinamide with dopamine receptors in vivo.
Topics: Animals; Catalepsy; Cerebellum; Corpus Striatum; Mice; Niacinamide; Receptors, Dopamine; Spiperone | 1989 |
The thieno[3,2-c]pyridine and furo[3,2-c]pyridine rings: new pharmacophores with potential antipsychotic activity.
Topics: Amphetamines; Animals; Avoidance Learning; Binding, Competitive; Catalepsy; Chemical Phenomena; Chem | 1989 |
Receptor affinity, neurochemistry and behavioral characteristics of the enantiomers of thioridazine: evidence for different stereoselectivities at D1 and D2 receptors in rat brain.
Topics: Animals; Benzazepines; Brain Chemistry; Catalepsy; Dopamine Antagonists; Male; Norepinephrine; Prazo | 1988 |
Synthesis and neuroleptic activity of a series of 1-[1-(benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl]benzim idazolone derivatives.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Benzimidazoles; Brain; Catalepsy; Catt | 1987 |
Chronic uridine treatment reduces the level of [3H]spiperone-labelled dopamine receptors and enhances their turnover rate in striatum of young rats: relationship to dopamine-dependent behaviours.
Topics: Adrenergic alpha-Antagonists; Age Factors; Animals; Catalepsy; Corpus Striatum; Male; Motor Activity | 1988 |
BRL 20596, a novel anilide with central dopamine antagonist activity.
Topics: Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Brain Chemistry; Catalepsy; Dextroamphet | 1986 |
Pharmacologic evaluation of dopaminergic receptor blockade by metoclopramide.
Topics: Animals; Behavior, Animal; Catalepsy; Dopamine; Haloperidol; Male; Metoclopramide; Motor Activity; P | 1986 |
Antidopaminergic effects of bisbenzyl and benzyl tetrahydroisoquinoline alkaloids.
Topics: Alkaloids; Animals; Apomorphine; Behavior, Animal; Benzylisoquinolines; Binding, Competitive; Catale | 1985 |
Simultaneous catalepsy and apomorphine-induced stereotypic behavior in mice.
Topics: Animals; Apomorphine; Catalepsy; Chlorpromazine; Domperidone; Drug Interactions; Haloperidol; Inject | 1985 |
Possible dissociation of central dopamine receptor antagonism and cataleptic behavior.
Topics: Animals; Apomorphine; Catalepsy; Haloperidol; Male; Prolactin; Rats; Rats, Inbred Strains; Receptors | 1985 |